Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Expected to Post Quarterly Sales of $852.43 Million

Wall Street brokerages expect that Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) will announce sales of $852.43 million for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $900.00 million and the lowest estimate coming in at $830.50 million. Jazz Pharmaceuticals reported sales of $607.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 40.3%. The business is expected to announce its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Jazz Pharmaceuticals will report full year sales of $3.60 billion for the current financial year, with estimates ranging from $3.49 billion to $3.67 billion. For the next financial year, analysts expect that the company will post sales of $3.82 billion, with estimates ranging from $3.49 billion to $4.30 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last issued its quarterly earnings results on Tuesday, March 1st. The specialty pharmaceutical company reported $3.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.68. The business had revenue of $896.73 million during the quarter, compared to analysts’ expectations of $866.71 million. Jazz Pharmaceuticals had a positive return on equity of 21.56% and a negative net margin of 10.65%. The firm’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.56 earnings per share.

Several equities research analysts have weighed in on the company. Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. Truist Financial upped their target price on Jazz Pharmaceuticals from $180.00 to $200.00 in a research note on Thursday, January 20th. Needham & Company LLC restated a “buy” rating and set a $215.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, February 7th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, March 3rd. Finally, The Goldman Sachs Group cut Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $202.00 to $196.00 in a research note on Wednesday, April 6th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $203.92.

Shares of JAZZ stock opened at $160.22 on Monday. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 1.52. The stock has a market cap of $9.89 billion, a P/E ratio of -29.40, a price-to-earnings-growth ratio of 1.39 and a beta of 0.87. The stock has a 50 day simple moving average of $157.05 and a 200 day simple moving average of $142.27. Jazz Pharmaceuticals has a 1 year low of $117.64 and a 1 year high of $189.00.

In related news, CEO Bruce C. Cozadd sold 10,772 shares of the stock in a transaction on Monday, April 4th. The stock was sold at an average price of $158.33, for a total value of $1,705,530.76. Following the completion of the sale, the chief executive officer now directly owns 346,062 shares in the company, valued at $54,791,996.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 6,372 shares of the stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $139.23, for a total value of $887,173.56. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its holdings in Jazz Pharmaceuticals by 344.4% during the 1st quarter. SG Americas Securities LLC now owns 24,519 shares of the specialty pharmaceutical company’s stock worth $3,817,000 after acquiring an additional 19,002 shares during the period. All Season Financial Advisors Inc. acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $222,000. Park Avenue Securities LLC grew its holdings in Jazz Pharmaceuticals by 41.7% during the 1st quarter. Park Avenue Securities LLC now owns 3,801 shares of the specialty pharmaceutical company’s stock worth $592,000 after acquiring an additional 1,119 shares during the period. Daiwa Securities Group Inc. grew its holdings in Jazz Pharmaceuticals by 3.1% during the 1st quarter. Daiwa Securities Group Inc. now owns 3,325 shares of the specialty pharmaceutical company’s stock worth $518,000 after acquiring an additional 100 shares during the period. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $45,000. Hedge funds and other institutional investors own 91.95% of the company’s stock.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Recommended Stories

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.